License Holds Promise For Schizophrenia?
INTRA-CELLULAR THERAPIES, INC.; Company receives license for central nervous system compounds
Intra-Cellular Therapies, Inc., (ITI) a privately held biopharmaceutical company focusing on the development of new therapeutics for neuropsychiatric and neurodegenerative disorders, announced that it has been granted an exclusive, worldwide license to a family of pre-clinical compounds from Bristol-Myers Squibb Company.
This license will "provide ITI with a portfolio of compounds." This means that ITI may soon have new treatments that are useful for schizophrenia, bipolar disorder, and even obsessive-compulisve disorder. "The compounds complement our internal pipeline of small molecule therapeutics developed using ITI's drug discovery platform," said Sharon Mates, PhD, and CEO of ITI.
Full Story:
http://tinyurl.com/848ww
Posted by Laura at June 25, 2005 02:46 PM
More Information on
Schizophrenia Biology
